Table 1

Patient demographics and clinical characteristicsa
Demographics and characteristics Brodalumab
Placebo SC IV
SC IV All 50 mg 140 mg 210 mg 420 mg 700 mg All Total
(N= 6) (N= 4) (N =10) (N= 6) (N= 6) (N= 6) (N= 6) (N= 6) (N= 30) (N= 40)
Females, n (%) 5 (83) 4 (100) 9 (90) 6 (100) 6 (100) 5 (83) 5 (83) 3 (50) 25 (83) 34 (85)
Race, n (%)
 White 4 (67) 2 (50) 6 (60) 3 (50) 2 (33) 1 (17) 5 (83) 1 (17) 12 (40) 18 (45)
 Black 1 (17) 1 (25) 2 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5)
 Latino 1 (17) 1 (25) 2 (20) 3 (50) 4 (67) 4 (67) 1 (17) 5 (83) 17 (57) 19 (48)
 Asian 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 1 (3) 1 (3)
Age (yr) 52 (10) 56 (12) 53 (10) 46 (12) 57 (9) 46 (10) 56 (7) 50 (6) 51 (10) 51 (10)
Height (cm) 162 (8) 163 (5) 163 (7) 159 (13) 158 (8) 158 (13) 168 (6) 161 (10) 161 (11) 161 (10)
Weight (kg) 75 (10) 101 (28) 85 (22) 80 (17) 77 (12) 64 (11) 81 (12) 79 (14) 76 (14) 79 (17)
BMI (kg/m2) 29 (4) 37 (9) 32 (7) 33 (14) 31 (3) 26 (3) 29 (4) 31 (4) 30 (7) 30 (7)
Tender/painful joint counts 24 (12) 30 (21) 26 (15) 23 (12) 40 (26) 32 (27) 42 (21) 32 (12) 34 (21) 32 (20)
Swollen joint counts 15 (15) 19 (8) 17 (12) 10 (6) 22 (13) 20 (7) 19 (11) 21 (16) 18 (11) 18 (11)
Patient global assessment of disease activity 72 (23) 57 (22) 67 (23) 57 (16) 68 (23) 51 (25) 44 (18) 54 (23) 55 (21) 57 (22)
Physician global assessment of disease activity 7.7 (1.8) 6.0 (1.8) 7.0 (1.9) 6.7 (2.1) 6.3 (2.2) 7.3 (2.0) 6.8 (1.9) 7.0 (0.9) 6.8 (1.8) 6.9 (1.8)
Patient global assessment of pain 72 (23) 63 (18) 68 (20) 60 (18) 71 (17) 49 (28) 49 (14) 60 (24) 58 (21) 60 (21)
HAQ-DI 1.4 (0.9) 1.4 (0.5) 1.4 (0.7) 1.3 (0.7) 1.7 (0.6) 1.7 (1.0) 1.5 (0.7) 1.7 (0.5) 1.6 (0.7) 1.5 (0.7)
CRP (mg/L) 15 (17) 26 (39) 19 (26) 7 (9) 7 (4) 28 (39) 24 (50) 33 (53) 20 (36) 20 (34)
ESR (mm/h) 27 (23) 39 (29) 32 (26) 19 (11) 16 (11) 23 (15) 23 (28) 41 (45) 24 (26) 26 (25)
RF-positive, n (%) 4 (67) 4 (100) 8 (80) 5 (83) 4 (67) 5 (83) 5 (83) 5 (83) 24 (80) 32 (80)

aBMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; IV, intravenous; RF, rheumatoid factor; SC, subcutaneous. All data are means (SD) unless otherwise indicated.

Martin et al.

Martin et al. Arthritis Research & Therapy 2013 15:R164   doi:10.1186/ar4347

Open Data